BioNTech SE (BNTX)vsInsmed Inc (INSM)
BNTX
BioNTech SE
$88.77
+2.26%
HEALTHCARE · Cap: $21.82B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
BioNTech SE generates 373% more annual revenue ($2.87B vs $606.42M). INSM leads profitability with a -2.1% profit margin vs -39.6%. BNTX appears more attractively valued with a PEG of 0.04. INSM earns a higher WallStSmart Score of 39/100 (F).
BNTX
Avoid35
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Safe zone — low bankruptcy risk
No standout strengths identified
Areas to Watch
Weak financial health signals
ROE of -5.9% — below average capital efficiency
Revenue declined 23.7%
Earnings declined 43.2%
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BNTX
The strongest argument for BNTX centers on PEG Ratio, Price/Book, Altman Z-Score. PEG of 0.04 suggests the stock is reasonably priced for its growth.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : BNTX
The primary concerns for BNTX are Piotroski F-Score, Return on Equity, Revenue Growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
BNTX carries more volatility with a beta of 1.53 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
BNTX generates stronger free cash flow (238M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 35/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioNTech SE
HEALTHCARE · BIOTECHNOLOGY · USA
BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?